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In recent years, administrative registry data has been used 
with increasing frequency in dermato-epidemiological 
studies (1, 2). A common approach to the identification 
of patients is through use of the International Classifica-
tion of Diseases, 10th revision (ICD-10) codes (2–4). This 
study aimed to validate the diagnostic code for psoriasis 
(ICD-10 L40.0) recorded in the Danish National Patient 
Register (5). 
The study was approved by the Danish Data Agency 
(ref. 2012-58-0004, j.no. VD-2018-286, I-Suite no.: 
6528) and the Danish Patient Safety Authority (j.no. 
3-3013-2654/1, ref. EMGW).
From among all patients seen in our department (the 
Department of Dermatology and Allergy, Herlev and 
Gentofte Hospital, Hellerup, Denmark), we randomly 
selected 100 adults and all children with a recorded 
diagnosis of psoriasis vulgaris in the National Patient 
Register ICD-10 code L40.0 between 1 January 2008 
and 23 October 2018. In case of multiple diagnoses of 
psoriasis during this period, the first of these was used 
as the index date. The criterion for validity was the use 
of terms consistent with psoriasis vulgaris with no other 
competing dermatological diagnosis (e.g. dermatitis or 
pustular psoriasis) in the patient’s medical chart on the 
same date that the diagnosis was recorded. Data extrac-
ted from the chart included age at recorded diagnosis, 
age of psoriasis onset, sex, psoriasis type, Dermatology 
Life Quality Index (DLQI), body surface area (BSA), 
Psoriasis Area Severity Index (PASI), location, potential 
triggers, first location, and familiar disposition. 
The study comprised a total of 137 patients, of whom 
100 were adults and 37 were children (Table I). Few 
patients had an identified trigger (n = 3), and BSA was 
reported in only 2 patients. The psoriasis diagnosis could 
not be verified in a total of 4 patients, 2 adults and 2 
children, from the medical chart on the same date as the 
diagnosis was recorded. In the medical chart 1 of the 2 
children was noted to definitively have psoriasis on a later 
date, whereas the 3 remaining patients were reported to 
have psoriasiform dermatitis. Consequently, the overall 
positive predictive value (PPV) of the study was 97.1% 
(95% confidence interval (95% CI) 95.5–98.1). In adults, 
the PPV was 98.0% (95% CI 95.7–99.1), and in children 
the PPV was 94.6% (95% CI 88.7–97.5). 
This study found a high PPV of the ICD-10 code for 
psoriasis in the Danish National Patient register. Re-
cently, a medical chart review found a similarly high PPV 
for diagnosis of atopic dermatitis in the same register (6). 
This demonstrates consistency in the use of ICD-10 codes 
in skin diseases in Denmark. However, as diagnoses were 
made by a dermatologist, the validity of diagnoses from 
other departments, e.g. emergency departments, might 
not be similar. Nevertheless, the given estimate of the 
PPV is considered conservative, as only patients with 
the diagnosis on the index date were included as cases. 
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Table I. Clinical and demographic characteristics of patients with 
L40 diagnosis
Adults (n = 100) Children (n = 37)
Psoriasis diagnosis, n (%)
  At index date 98 (98) 35 (95)
  At a later time-point 0 1 (3)
Psoriasiform dermatitis, n (%) 2 (2) 1 (3)
Psoriasis type, n (%)
  Vulgarisa 80 (80) 25 (71)
  Guttateb 7 (7) 2 (2)
  Pustularc 0 0
Sex, n (%)
  Male 58 (58) 18 (49)
  Female 42 (42) 19 (51)
Age, years, mean ± SD 47.9 ± 15.9 12.6 ± 3.5
Age of onset, years, mean ± SD 28.0 ± 16.2 9.1 ± 4.0
Disease duration, years, mean ± SD 19.7 ± 16.7 3.0 ± 2.9
PASI, mean ± SD [range] 10.3 ± 6.1 [0.6–34.9]
(n = 61)
7.8 ± 3.8 [0–13.6]*
(n = 18)
DLQI, mean ± SD [range] 10.8 ± 6.7 [1–27]
(n = 43)
11.2 ± 11.2 [1–29]
(n = 6)
Patients with reported familial 
history, n (%)
80 (80) 33 (89)
  Any 45 (45) 23 (62)
  Father 22 (22) 8 (22)
  Mother 11 (11) 7 (19)
  Siblings 8 (8) 4 (11)
  Grandparents 6 (6) 5 (14)
Patients with reported anatomical 
involvement, n (%)
67 (67) 31 (84)
  Hands 18 (18) 2 (5)
  Feet 10 (10) 2 (5)
  Inverse 9 (9) 1 (3)
  Genital 4 (4) 5 (14)
  Scalp 34 (34) 27 (73)
  Knee 14 (14) 2 (5)
  Elbows 24 (24) 7 (19)
  Face 10 (10) 11 (30)
Patients with reported first 
involvement, n (%)
11 (11) 14 (38)
  Hands 1 (1) 2 (5)
  Scalp 6 (6) 7 (19)
  Elbows 1 (1) 1 (3)
  Knee 1 (1) 0 (0)
  Other 3 (3) 5 (14)
*One patient was well-treated with a biologic at referral with a PASI of 0.
aThe term(s) psoriasis vulgaris and/or plaque psoriasis are used in the chart. bThe 
term guttate has been used in the chart. cThe terms pustular and/or palmoplantar 
pustulosis are used in the chart.
PASI: Psoriasis Area and Severity Index; DLQI: Dermatology Life Quality Index; 
SD: standard deviation. 
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The observed mean PASI corresponds to moderate-to-
severe psoriasis (7) consistent with that seen in patients 
receiving systemic (mean ± standard deviation (SD), PASI 
of 8.3 ± 6.4) (8) and biologics (PASI of 13.2 ± 8.1) (9), 
which is consistent with this being the first time most of 
the patients were seen in a university hospital. However, 
the recorded PASI ranged from negligible to very severe 
disease, which might be attributed to the fact that some 
patients were already receiving systemic treatments at 
referral. The high proportion of children with a familial 
history of psoriasis is consistent with type 1 psoriasis 
showing a strong genetic predisposition (10). 
This study was limited by the single-centre design; 
however, since all hospital dermatology departments 
in Denmark are academic university departments, we 
suspect that similar findings would apply at other de-
partments in the country.
In summary, this study suggests that the use of the 
ICD-10 code L40.0 to identify patients with psoriasis is 
a valid approach in registry-based studies. 
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